Stay updated on Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial

Sign up to get notified when there's something new on the Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The footer’s site revision label changed from v3.7.1 to v3.7.2 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-19T20:46:28.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision label updated from v3.7.0 to v3.7.1 while the page remained a 403 error page.
    Difference
    0.2%
    Check dated 2026-10-13T03:51:10.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    33 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error instead of the study record content. This indicates access is blocked to this entry.
    Difference
    19%
    Check dated 2026-09-21T22:53:11.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.6.6, replacing the previous Revision: v3.6.5. This reflects a minor update to the page's metadata rather than changes to the study details.
    Difference
    0.1%
    Check dated 2026-08-31T17:00:24.000Z thumbnail image
  6. Check
    75 days ago
    Change Detected
    Summary
    The page’s revision tag was updated to v3.6.5, replacing the previous v3.6.4 to reflect a new page version. This change does not modify study data or other critical content.
    Difference
    0.1%
    Check dated 2026-08-10T10:46:15.000Z thumbnail image
  7. Check
    90 days ago
    Change Detected
    Summary
    The page's revision tag was updated from v3.6.3 to v3.6.4, indicating a new build of the site content. This appears to be a metadata/version-control change rather than a modification to the study details or user-facing information.
    Difference
    0.1%
    Check dated 2026-07-27T05:54:38.000Z thumbnail image

Stay in the know with updates to Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ipilimumab Nivolumab in PD-1-resistant Lung Cancer Clinical Trial page.